Skip to main content

1 Result(s)

within Fangwei Jie Remove this filter

and

  1. No Access

    Article

    Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer

    Background Dulanermin is a recombinant soluble human Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) that activates apoptotic pathways by binding to proapoptotic death...

    Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen… in Investigational New Drugs (2018)